Hong Kong Stock Continuous Pullback Attracts Capital Inflow, Huatai Pinebridge Hang Seng Series ETF Helps Navigate Recovery Opportunities

Due to multiple factors such as the Federal Reserve’s policy shift and geopolitical sentiment, the Hong Kong stock market has recently been under significant pressure, with major indices continuing to fluctuate downward. On March 23, 2026, the Hang Seng Index briefly fell below the 25,000-point mark, and the Hang Seng Tech Index also dropped below 4,800 points, both hitting their lowest levels of the year.

As the overall Hong Kong stock market retraced, valuation pressures on key sectors such as technology, healthcare, and consumer goods eased, gradually highlighting their investment value. Market attention to index products like the Huatai-PineBridge Hang Seng Tech ETF (513130), Huatai-PineBridge Hang Seng Biotech ETF (513930), Huatai-PineBridge Hang Seng Consumer ETF (520520), and Huatai-PineBridge Hang Seng Innovative Drug ETF (520500) continued to grow.

Wind data shows that all domestic ETFs tracking Hang Seng company indices experienced a net capital outflow from March 13 to March 17, 2026. However, from March 18 to March 20, they successfully reversed the trend, achieving three consecutive days of net capital inflow with a total net inflow of 2.316 billion yuan. This indicates that funds are gradually beginning to allocate to high-quality core assets in Hong Kong stocks via ETFs, reflecting a positive outlook for subsequent market recovery.

In terms of Hong Kong stock investment tools, Huatai-PineBridge has a well-developed product lineup, including multiple high-quality Hang Seng series ETFs such as the Huatai-PineBridge Hang Seng Tech ETF (513130), Huatai-PineBridge Hang Seng Biotech ETF (513930), Huatai-PineBridge Hang Seng Consumer ETF (520520), and Huatai-PineBridge Hang Seng Innovative Drug ETF (520500). These cover core sectors of the Hong Kong market, providing investors with convenient and efficient channels for strategic deployment.

Among them, the Hang Seng Tech ETF (513130), which covers leading Hong Kong tech companies, has seen four consecutive days of share growth, with assets surpassing 80 billion shares. The Hang Seng Consumer ETF (520520) has also attracted capital, with its shares increasing by 78.57% over the past two trading days. In the healthcare sector, the Hang Seng Innovative Drug ETF (520500) focuses precisely on the innovative drug core sector, while the Hang Seng Biotech ETF (513930) balances CXO and innovative drug fields to meet diverse investor needs.

As one of the earliest ETF managers in the market, Huatai-PineBridge has been deeply engaged in index investment for nearly 20 years, creating the market’s first dividend-themed ETF and the first cross-market ETF, the CSI 300 ETF (Huatai-PineBridge). By the end of 2025, the company’s ETFs had generated over 164 billion yuan in cumulative profits for holders over the past two years, making it one of only four fund companies in the market with cumulative profits exceeding 100 billion yuan during the same period. Regarding fee rates, 77.8% of the company’s ETF assets adopt the lowest fee structure in the current market for equity index funds (management fee of 0.15% per year + custody fee of 0.05% per year).

MACD golden cross signals have formed, and these stocks are showing good upward momentum!

Massive information and precise analysis are available on Sina Finance APP.

Editor: Shi Xiuzhen SF183